AiCure

ALS Therapy Development Institute

ALS Therapy Development Institute, Neurimmune partner for ALS

Friday, December 6, 2013 12:51 PM

The ALS Therapy Development Institute (ALS TDI) and its wholly-owned subsidiary, Anelixis Therapeutics, a translational medicine and drug development company, have partnered with Swiss biotech company Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig's disease.

More... »


ALS TDI, Gladstone Institutes to discover potential ALS treatments

Wednesday, December 5, 2012 09:44 AM

The ALS Therapy Development Institute (ALS TDI), aimed at developing effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS), and the Gladstone Institutes, a nonprofit biomedical-research organization, have formed a research collaboration to speed the discovery of potential treatments for ALS through the preclinical drug development process.

More... »


ALS TDI, Regenesance partner on Lou Gehrig’s disease

Monday, May 7, 2012 12:35 PM

Cambridge, Mass.-based ALS Therapy Development Institute (ALS TDI), one of the largest ALS drug development centers, has entered into a partnership with Netherlands-based biotech Regenesance to investigate a potential treatment for Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

More... »

ALS Therapy to launch phase II trial of TDI 132

Wednesday, February 15, 2012 04:03 PM

The ALS Therapy Development Institute, a nonprofit biotech, will be launching a phase II clinical trial on TDI 132 (fingolimod)—currently used as treatment for multiple sclerosis—as a potential treatment for ALS (Lou Gehrig's disease). 

More... »

Biogen Idec, UCB partner in ALS research

Monday, December 19, 2011 02:39 PM

The ALS Therapy Development Institute (ALS TDI) has formed a research agreement with Biogen Idec and UCB to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's or Motor Neuron Disease. Financial terms of the agreement were not disclosed.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs